Cardarine

Wang et al. (2003, PNAS) — independent Salk Institute study: GW501516 activated fatty acid beta-oxidation in skeletal muscle of obese rhesus monkeys and attenuated metabolic syndrome markers. Wang et al. (2004, PLOS Biology) — independent Salk Institute: PPARδ activation (via GW501516 and transgenic overexpression) induced the complete aerobic exercise phenotype in skeletal muscle; sedentary treated animals ran 70% farther than controls. Narkar et al. (2008 [3], Cell) — combining GW501516 with AICAR (an AMPK activator) produced even more dramatic endurance enhancement, described as 'exercise in a pill.' Community experience: consistent and repeated reports of dramatically improved cardiovascular endurance, reduced perceived effort at given exercise intensities, and improved fat oxidation during training. Grade B for animal model findings (independent labs; replicated); Grade E for human endurance effects (community self-reports; no controlled human endurance study).

Human Phase 1/2 studies documented: HDL increase up to 16.9% at 10 mg/day; triglyceride reduction; LDL reduction; VLDL reduction. These are among the most favorable lipid profile changes seen with any pharmacological intervention. The Phase 2 data in primate and human models was the primary positive finding that kept GW501516 in development through 2007. Park et al. (2021) [4] — a short-term human study documented 20% liver fat reduction at 10 mg/day in just two weeks. Grade B: controlled short-term human data; GSK-sponsored but the lipid findings have been cited independently.

PPARδ activation fundamentally shifts the body's fuel utilization toward fat oxidation at rest and during exercise. This produces the 'fat burning' effects the community values: reduced fat mass, preserved lean mass during caloric restriction, and improved body composition metrics. The muscle fiber type switching (Type IIb → Type IIa) contributes to a more metabolically active muscle phenotype. Grade B for the mechanism and animal data; Grade E for human body composition effects in the community context.

Short-term human studies showed improved insulin sensitivity and reduced inflammatory markers. The metabolic improvements were part of the original therapeutic rationale and have been partially confirmed in the limited human studies conducted before program termination. Grade B: limited human data; consistent with mechanism and animal models.

GW501516 is a synthetic small molecule (molecular weight ~453 Da). It is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARδ, also called PPARβ or PPARβ/δ). PPARδ is a nuclear receptor — a transcription factor that, when activated, directly binds to DNA response elements and changes gene expression programs in target tissues. GW501516 binds PPARδ with extraordinary selectivity (Ki = 1 nM; >1,000-fold selectivity over PPARα and PPARγ). When it binds PPARδ, the receptor recruits the coactivator PGC-1α, forming a complex that upregulates the expression of fatty acid oxidation enzymes, fatty acid transport proteins, and mitochondrial biogenesis genes in skeletal muscle and liver.

NOT A SARM — THIS MATTERS

GW501516 is routinely and incorrectly marketed as a SARM (selective androgen receptor modulator). It has zero androgen receptor activity. It does not affect testosterone levels. It does not cause HPTA suppression. It does not produce androgenic side effects. It is not in the same chemical class or regulatory category as SARMs. The SARM misclassification is commercially motivated — SARMs are popular, and marketing cardarine alongside them generates sales. It is pharmacologically incorrect. The performance effects of GW501516 come entirely from PPARδ activation and the resulting changes in fatty acid metabolism and mitochondrial gene expression — a completely different mechanism from anything that operates at the androgen receptor.

GW501516 has good oral bioavailability — it is taken as an oral solution or capsule, not injected. Half-life in humans: approximately 16-24 hours, supporting once-daily dosing. Hepatically metabolized (CYP3A4 pathway). Protein binding >99% (highly albumin-bound). The long half-life and oral route make it practically convenient, which has contributed to its widespread community adoption. Standard formulations: oral liquid solution at 10-20 mg/mL in DMSO/PEG blend, or encapsulated powder. Do not inject — the liquid formulations contain DMSO and PEG solvents that are toxic if injected.

USADA WARNING — ATHLETES CAN TEST POSITIVE WITHOUT KNOWING

USADA has specifically identified GW501516 as a supplement contaminant. Athletes have tested WADA-positive for GW501516 metabolites after using supplements not labeled to contain it. This represents a career-ending WADA violation through no intentional use. Any athlete in tested sport who competes in a jurisdiction with WADA anti-doping requirements should screen all supplements rigorously for GW501516 contamination — particularly any supplement marketed for fat burning, endurance, or metabolic enhancement. The presence of GW501516 in contaminated supplements is one of the documented real-world harms of the compound's black market production.

PPARδ is expressed throughout the body but has its highest functional relevance in skeletal muscle, where it regulates the shift between carbohydrate and fat as fuel sources. When GW501516 binds PPARδ in skeletal muscle cells, it upregulates a coordinated program of gene expression: FABP3 (fatty acid binding protein, enhancing intracellular fatty acid transport); CPT1 (carnitine palmitoyltransferase, rate-limiting for mitochondrial fat uptake); PDHK4 (pyruvate dehydrogenase kinase, which reduces carbohydrate oxidation by phosphorylating pyruvate dehydrogenase); GLUT4 (enhancing glucose uptake capacity); and UCP2/UCP3 (mitochondrial uncoupling proteins, increasing thermogenesis). The net effect: skeletal muscle becomes dramatically more capable of oxidizing fat as fuel — which is what elite endurance athletes develop over years of aerobic training. GW501516 produces this shift pharmacologically. Grade A for the mechanism (PPARδ biochemistry is well-established).

Wang et al. (PLOS Biology, 2004) showed that transgenic mice overexpressing PPARδ in skeletal muscle had dramatically increased Type I and IIa oxidative fiber content — the fiber types that characterize endurance-trained athletes. These mice ran longer, used more fat during exercise, and had a phenotype remarkably similar to trained endurance athletes. GW501516 produced similar (though less complete) fiber type switching in untrained animals. The 70% endurance improvement came primarily from this metabolic reprogramming — the muscles could sustain aerobic activity longer because they had access to essentially unlimited fat stores rather than limited glycogen. Grade B: independent landmark study (Salk Institute, not GSK); animal model; the mechanism is now well-understood.

THE MECHANISTIC EXPLANATION FOR CARCINOGENICITY

PPARδ activation does not just regulate fatty acid oxidation in muscle. PPARδ is also expressed in the gut epithelium, liver, skin, and other tissues — and in those contexts, PPARδ signaling promotes cell survival, proliferation, and resistance to apoptosis. PPARδ is upregulated in colon cancer, breast cancer, and lung cancer, and its activation promotes tumor growth by inhibiting apoptosis (through Bcl-2 upregulation), promoting angiogenesis (through VEGF), and accelerating cell cycle progression. Essentially: the gene expression program that makes fat-burning and cellular survival efficient in muscle is also a gene expression program that makes cancer cells survive better in tissues that express PPARδ at baseline. GW501516 doesn't distinguish between 'good' PPARδ activation in muscle and 'bad' PPARδ activation in pre-cancerous colon epithelial cells. It activates all PPARδ everywhere. The cancer finding in animal studies was not a pharmacological accident — it was a mechanistically predictable consequence of systemic PPARδ agonism in tissues that are already PPARδ-expressing and include rapidly dividing cell populations.

GW501516 also activates AMPK (AMP-activated protein kinase) indirectly — through PPARδ-driven changes in cellular energy status that raise AMP/ATP ratios. This AMPK activation contributes additional metabolic benefits including improved insulin sensitivity and mitochondrial biogenesis. The AMPK activation mechanism is the same mechanism that MOTS-c targets directly. In the context of GW501516, it amplifies the metabolic benefits but also contributes to the complex cellular survival signaling that makes the carcinogenicity risk difficult to separate from the therapeutic benefits.

The two-year carcinogenicity studies conducted by GlaxoSmithKline in Han Wistar rats (standard regulatory toxicology species) used doses of 5 mg/kg/day and 40 mg/kg/day. By allometric scaling, these correspond to approximately 50-400 mg/day human-equivalent (vs community use of 10-20 mg/day). The results: tumor development in multiple organ systems including liver, stomach, skin (squamous cell carcinoma and papilloma), urinary bladder, tongue, and intestinal tract. Mouse studies showed intestinal adenoma development. The key finding was not merely increased cancer incidence — it was rapid tumor development across multiple organ sites simultaneously, at both the lower and higher dose levels studied.

The carcinogenicity studies have not been published as full peer-reviewed papers. They exist as GSK conference abstracts and internal regulatory submissions. The fact that they have not been published is not evidence of fabrication — pharmaceutical companies routinely do not publish negative development findings in full — but it does mean the complete data is not independently reviewable. The termination of the GSK program, the consistency of the finding across multiple organ sites and multiple species, and WADA's response in 2009 all provide strong corroboration that the signal was genuine.

WHY THE CARCINOGENICITY FINDING IS SERIOUS — NOT DISMISSIBLE

The community's most common response to the cancer data is: 'The doses in rat studies were much higher than what people use. Of course they caused cancer — everything causes cancer at high enough doses.' This argument contains a critical error of understanding about how pharmaceutical carcinogenicity testing works. Two-year rodent carcinogenicity studies are NOT designed to show that a compound causes cancer at high doses. Every compound causes some toxicity at high enough doses. The carcinogenicity studies are designed to be sensitive enough to detect compounds that would cause ONLY A MARGINAL INCREASE in human cancer risk — 5-10% above baseline tumor rates at doses translated to human exposure. They use doses that would produce plasma concentrations 5-10x above typical human therapeutic exposure. A compound that causes rapid multi-organ tumor development in these studies — not marginal increases, but rapid, multi-systemic tumor development at the lower dose level — has failed the test that is designed to detect even minor human carcinogenic potential. GW501516 did not marginally fail this test. It failed catastrophically, which is why GSK terminated the program rather than adjusting the dose.

Recent independent research (2024-2025) has identified additional carcinogenic mechanisms not characterized in the original GSK studies. Multiple studies have found that GW501516 facilitates tumor immune escape — it activates signaling pathways in the tumor microenvironment that suppress anti-tumor immune responses, potentially allowing established cancers to progress more rapidly. A 2025 study found GW501516 activates cancer growth pathways in some tumor models. These findings do not simply confirm the original animal data — they extend the potential cancer risk to contexts (accelerating established tumors, immune evasion) that were not identified in the original two-year studies. The recent mechanistic research is moving in the opposite direction from exonerating GW501516.

No published study has specifically linked cardarine use to cancer development in human users. This absence needs careful interpretation. Human cancer typically has a latency period of 15-30 years between initial carcinogen exposure and clinical cancer diagnosis. GW501516 entered significant community use in the early 2010s — meaning that even if it causes cancer in humans at community doses, the cancers would not be expected to present clinically until the late 2020s through the 2040s in many users. The 'no documented human cases' statement is not reassurance — it is an honest statement of where we are in time. The absence of cases is not the same as safety. It is the absence of sufficient time.

GW501516 is an oral compound. It is sold as oral liquid (commonly 10-20 mg/mL in DMSO/PEG or ethanol/PEG blend) or as powder capsules. The oral route matches its pharmacology (good oral bioavailability, once-daily dosing appropriate to the 16-24 hour half-life) and the formulation available. Do not inject liquid formulations — the DMSO and PEG solvents are tissue-toxic if injected.

Protocol

Dose

Duration

Frequency

Notes

Conservative / entry

5-10 mg/day

4-6 weeks

Daily, oral, with or without food

Lowest community dose; assesses individual response

Standard community

10-20 mg/day

6-8 weeks

Daily, oral

Most commonly reported; matches doses in short-term human lipid studies

Athlete / advanced

20 mg/day

6-8 weeks maximum

Daily, oral

Upper community limit; note WADA S4.4 complete ban

GSK carcinogenicity study (reference)

5 mg/kg/day (~350 mg for 70kg human, rat-allometric)

104 weeks continuous

Daily

The dose that produced multi-organ tumors — not a target, a reference point

The community convention of 8-week maximum cycles reflects awareness that continuous long-term use is the context where carcinogenicity risk is most relevant — two-year continuous dosing is what produced the tumor findings. Whether 8-week cycles with breaks meaningfully reduce cancer risk is unknown. The carcinogenicity mechanism (PPARδ activation promoting cell survival and proliferation in sensitive tissues) is not obviously cycle-limited — a pre-cancerous cell that receives PPARδ-driven survival signals for 8 weeks may not simply 'reset' during a 4-week break. This is speculation; there is no data on cycle-based carcinogenicity risk. The 8-week limit is community convention, not evidence-based safety guidance.

Once daily oral dosing. No specific food requirement, though some users report reduced GI discomfort when taken with food. Morning dosing is community default for consistency with other performance-oriented compounds. No circadian timing requirement specific to PPARδ pharmacology.

Cardarine is most commonly used in cutting cycles (caloric deficit, fat loss goal) where its fat oxidation and endurance properties complement the reduced caloric intake. It is also used in endurance sport performance contexts where the VO₂max and exercise capacity improvements are the primary goal. Common stacking companions: Ostarine (MK-2866) for muscle preservation during cut; RAD-140 for anabolic support. These stacks are common in the SARM/performance community. Note: SARMs are also associated with significant health risks and WADA violations — stacking cardarine with SARMs compounds both the regulatory and health risk profiles.

The short-term side effect profile of GW501516 at community doses (10-20 mg/day for 4-8 weeks) is actually quite mild compared to other performance-enhancing compounds: no testosterone suppression (not hormonal), no androgenic side effects, no liver toxicity signal in short-term human studies, no significant cardiovascular adverse events at these doses. The community's experience is broadly consistent with a clean short-term profile. This mild short-term profile is part of what makes GW501516 so attractive and so dangerous: the acute tolerability creates no immediate warning signal that corresponds to the long-term carcinogenic risk.

• Nausea: mild and occasional; usually resolves.
• Headache: occasionally reported; self-limiting.
• Mild GI discomfort: managed with food co-administration.
• No testosterone suppression: confirmed — GW501516 has no androgen receptor activity.
• No lipid adverse effects at community doses: at 10-20 mg/day, lipid effects are actually favorable (HDL increase, triglyceride reduction).

THE CANCER RISK IS NOT 'ONE OF SEVERAL SIDE EFFECTS'

In standard compound chapters, side effects are listed in order of frequency and severity, with serious effects highlighted. For GW501516, this structure is inappropriate. There is one side effect that dominates all others: the compound caused rapid, multi-organ tumor development in multiple animal species in GSK's carcinogenicity studies. This is not a 'possible' or 'theoretical' risk to be listed alongside nausea and headache. It is the reason a major pharmaceutical company halted a promising drug program that was producing excellent Phase 2 human results. The community's short-term tolerability experience is not evidence that this risk is absent — it is evidence that we have not waited long enough for long-term cancer latency to manifest.

• Active malignancy or cancer history: PPARδ activation supports tumor cell survival and immune evasion. This is not a theoretical concern — it is the documented mechanism of carcinogenicity. Active malignancy is an absolute contraindication.
• Pregnancy: carcinogen exposure during pregnancy with potential transplacental exposure to the fetus. Absolute contraindication.
• Children and adolescents: rapidly proliferating cells are most sensitive to carcinogens. Absolute contraindication.
• Tested athletes: WADA S4.4 ban; supplement contamination risk adds violation exposure even without intentional use. Complete prohibition.

GW501516 is not FDA-approved. The FDA classifies it as an unapproved new drug — meaning its manufacture, marketing, and sale as a dietary supplement or medication is illegal in the United States. The black market production of GW501516 by research chemical vendors is not legally regulated, not quality-controlled by pharmaceutical standards, and not monitored for contamination or accurate dosing. A compound with documented carcinogenicity concerns is being produced and sold in environments with no regulatory oversight. This is a layered risk: carcinogenicity from the compound itself, plus the contamination, dosing inaccuracy, and unknown adulterant risks of black market production. WADA ban: S4.4 Metabolic Modulators since 2009, at all times, in and out of competition, no TUE pathway.

The dose gap is real: 5 mg/kg/day in rats ≈ 50 mg/day human-equivalent; 40 mg/kg/day ≈ 400 mg/day. Community doses are 10-20 mg/day. The counterargument: two-year rodent carcinogenicity studies are specifically designed to detect compounds that would cause only marginal cancer risk increases in humans, using doses that are 5-10x above typical human therapeutic exposure — not 100x above. The fact that GW501516 caused multi-organ tumors at the lower dose level of these studies, which is only 3-5x above typical community doses by allometric scaling, is among the most concerning carcinogenicity signals in drug development. The dose argument provides less reassurance than the community assumes.

No published study has specifically linked cardarine use to a human cancer case. This is true. The relevant response: (1) typical human cancer latency is 15-30 years — the peak of cardarine community use began in the early 2010s, meaning the cancer cases that would result from that exposure, if they occur, would not be expected until the late 2020s through 2040s; (2) attributing any individual's cancer to a specific compound in the absence of a controlled study is scientifically impossible; (3) the absence of documented cases is consistent with both 'it doesn't cause cancer in humans at these doses' and 'we haven't waited long enough.' Current evidence cannot distinguish these possibilities.

This is the weakest counterargument. Rodent carcinogenicity studies are specifically validated and required by regulatory agencies precisely because they are predictive of human carcinogenicity. The two-year rat study is the single most powerful pre-clinical tool for detecting human carcinogens before they enter widespread use. When a compound fails this test — particularly in multiple species with multi-organ tumor development — regulatory agencies treat this as strong evidence of human carcinogenic potential. The fact that human cancer has not been proven does not mean the animal data is irrelevant. It means the human evidence is not yet available.

Community self-reporting is not a cancer surveillance system. Healthy young athletes using a compound for 8-week cycles will not observe cancer within a relevant timeframe, and would have no mechanism to know whether their cumulative exposure is creating DNA damage or early carcinogenic changes. The absence of self-reported harm is not evidence of safety for a compound whose cancer risk operates on a 15-30 year latency. This is why pharmaceutical carcinogenicity testing exists — because human self-observation cannot detect long-latency carcinogenic risks until it is too late.

• Shortest possible cycles: 4-6 weeks vs the community standard of 8 weeks. Less cumulative PPARδ exposure at any given dose.
• Lowest effective dose: 10 mg/day rather than 20 mg/day. The performance benefits at 10 mg are documented in human studies; 20 mg adds unknown additional carcinogenic burden.
• Longest possible breaks: 12-16 weeks off between cycles, not the common 4-8 week breaks.
• Do not combine with other carcinogen-risk compounds: SARMs (most have documented LH/FSH suppression and uncertain long-term safety profiles), prohormones, or other compounds with mutagenic or carcinogenic signals.
• Annual cancer screening: anyone with significant cardarine exposure history should discuss targeted cancer surveillance with a physician — baseline colonoscopy, skin examination, liver function panels. These do not eliminate cancer risk but may enable earlier detection.
• Do not use if any personal or family cancer history exists: the combination of an established genetic cancer predisposition with a PPARδ agonist that promotes tumor cell survival is particularly concerning.

• You are an athlete in tested sport — WADA S4.4 ban; supplement contamination creates risk even without intentional use
• You have any personal cancer history or strong family cancer history
• You are pregnant or attempting conception
• You are under 25 — younger age at carcinogen exposure correlates with higher lifetime cancer risk
• You are using other compounds with hepatotoxic or carcinogenic profiles

GW501516 produced by black market research chemical vendors is not subject to pharmaceutical quality control. Dose accuracy, purity, and contamination risk are all higher than for compounds produced under pharmaceutical oversight. HPLC purity documentation is essential. The FDA prohibition on its marketing creates a supply chain where every vendor is operating outside the regulatory framework designed to ensure safety. This adds unknown risk on top of the known carcinogenic risk of the compound itself.

Wang YX, Lee CH, Tiep S, et al. (2003). Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell. 113(2):159-170. [Independent Salk Institute; PPARδ activation in skeletal muscle; fat oxidation mechanism; foundational endurance pharmacology]

Wang YX, Zhang CL, Yu RT, et al. (2004). Regulation of muscle fiber type and running endurance by PPARδ. PLOS Biology. 2(10):e294. [Independent Salk Institute; transgenic PPARδ mice + GW501516; 70% endurance increase; fiber type switching; the most important performance study]

Narkar VA, Downes M, Yu RT, et al. (2008). AMPK and PPARδ agonists are exercise mimetics. Cell. 134(3):405-415. [GW501516 + AICAR combination; 'exercise in a pill' framing; Salk Institute independent]

Bays HE, et al. (Phase 2 GSK studies). GW501516 in dyslipidemia: HDL increase up to 16.9%; lipid profile improvements at 10 mg/day. [GSK Phase 1/2 clinical data; short-term lipid findings in humans]

Park BH, et al. (2021). GW501516 reduces liver fat content by approximately 20% in 2 weeks at 10 mg/day in humans with elevated liver fat. [Post-GSK independent human study; liver fat application]

GlaxoSmithKline. (2007). Termination of GW501516 (Cardarine) development. GSK Press Release and regulatory submission abstracts. [Two-year carcinogenicity studies in Han Wistar rats: multi-organ tumor development at 5 mg/kg/day and 40 mg/kg/day. Intestinal adenoma in mice. Program terminated. Full papers not published.]

Mitchell JA, et al. (Pulmonary Circulation, 2019). PPARβ/δ a potential target in pulmonary hypertension blighted by cancer risk. PMC6475847. [Reviews GSK carcinogenicity abstracts; positions cancer risk in context of PPARδ pharmacology; independent academic review]

USADA. (2026) [6]. What Should Tested Athletes Know About GW1516? [Supplement contamination risk documented; S4.4 ban confirmed; zero tolerance policy]

WADA. (2025). 2025 Prohibited List. S4.4.1 PPARδ agonists — GW501516 listed explicitly; banned at all times since 2009.

Multiple authors. (2024-2025). GW501516 facilitates tumor immune escape and activates cancer growth pathways. [Recent independent research extending the carcinogenicity mechanism; tumor microenvironment immune suppression; GW501516 supporting established cancer progression through new mechanisms]

Compound

Performance Benefit

Carcinogenicity

Human Cancer Data

WADA

GW501516 (Cardarine)

70% endurance increase (animal); HDL +17% (human)

Multi-organ tumors; multiple species; multiple doses; GSK terminated program

Not documented; insufficient follow-up time

S4.4 banned since 2009

Testosterone

Muscle mass, strength, recovery

No carcinogenicity signal at physiological doses; prostate concern at supraphysiological

Some prostate cancer association at high doses; complex

S1 banned

SLU-PP-332

70% endurance (sedentary mice); no human data

Not studied in 2-year carcinogenicity studies

Not studied

S4.4 banned

MOTS-c

Exercise mimicry via AMPK; metabolic

No carcinogenicity studies; no concerning signal

No documented concerns

S4.4 banned

Retatrutide

28.7% weight loss Phase 3

No carcinogenicity signal beyond GLP-1 class thyroid warning

Thyroid C-cell concern — class warning only; no confirmed human cases

Not banned

• 'It only caused cancer in animals, not humans': the reason it hasn't caused documented cancer in humans is that the animal carcinogenicity signal was severe enough to prevent long-term human studies. This is a feature of the regulatory system protecting humans, not evidence of human safety.
• 'Cycling reduces the cancer risk': plausible hypothesis; not established. The animal studies used continuous dosing. Whether episodic PPARδ activation reduces carcinogenic risk is unknown.
• 'Thousands of people use it without problems': cancer latency of 15-30 years makes community self-observation useless for long-latency carcinogenicity assessment. 'Without problems' means 'without acute problems' — which is true for most carcinogens in the short term.
• 'Lower doses must be safer': lower doses reduce exposure but the compound's carcinogenicity mechanism (PPARδ activation in proliferative tissues) is active at doses that produce its desired effects. The performance benefits come from the same mechanism as the carcinogenic risk.

— End of Cardarine —

THE PEPTIDE BIBLE | Cardarine (GW501516) | For Research & Educational Purposes Only